

Angelman Syndrome

Indications for Ordering

Angelman syndrome (AS) and Prader-Willi syndrome (PWS) by methylation

- Establish diagnosis in individuals with clinical symptoms

UBE3A gene sequencing

- Establish diagnosis in individuals with clinical symptoms of AS and normal DNA methylation

Test Description

DNA methylation

- Methylation sensitive polymerase chain reaction/fluorescence monitoring

UBE3A sequencing

- Bidirectional sequencing of entire *UBE3A* coding region and intron/exon borders

Tests to Consider

Primary tests

[Angelman Syndrome and Prader-Willi Syndrome by Methylation-Sensitive PCR 2005077](#)

- Preferred initial diagnostic test for AS or PWS

[Angelman Syndrome \(*UBE3A*\) Sequencing 2005564](#)

- Second-tier test for the diagnosis of AS
- Order if suspicion for AS remains after normal methylation analysis

Related tests

[Angelman Syndrome and Prader-Willi Syndrome by Methylation-Sensitive PCR, Fetal 2012232](#)

- Prenatal testing for AS or PWS
- Identifies cases resulting from molecular mechanisms that produce abnormal methylation patterns

[Chromosome FISH, Metaphase 2002299](#)

- Follow-up for abnormal methylation test for AS

[Cytogenomic SNP Microarray 2003414](#)

- Follow-up for abnormal methylation test for AS

[Rett Syndrome \(*MECP2*\), Sequencing and Deletion/Duplication 0051614](#)

- Rule out an *MECP2* gene mutation in individuals with clinical features of AS who lack a molecular abnormality involving 15q11.2-q13

[Familial Mutation, Targeted Sequencing 2001961](#)

- Useful when a pathogenic familial variant identifiable by sequencing is known

Disease Overview

Incidence – 1/15,000

Age of onset – 6-12 months

Symptoms

- Normal development until initial symptoms – oral-motor incoordination and feeding difficulty
- Severe developmental delay
- Severe speech impairment (little or no expressive language)
- Gait ataxia/tremulousness of limbs
- Unique behaviors – eg, overly happy
- Secondary microcephaly (by age 2)
- Seizures (by age 3)
- Sleep disturbances
- Characteristic EEG pattern
- Autistic spectrum features
- Dysmorphic features – flat occiput, wide mouth, protruding tongue, prognathism, strabismus
- Hypopigmentation of skin, eyes, hair

Genetics

Gene – *UBE3A*

- Other molecular mechanisms

Inheritance – altered/inactivated/disrupted or absent maternally imprinted *UBE3A*

De novo mutations – 70-90%

Etiologies

- Maternal deletion of 15q11.2-q13 (70-90%)
- Paternal uniparental disomy (UPD) for chromosome 15 (3-7%)
- *UBE3A* gene mutation (11%)
- Imprinting center defect (2-4%)
- Unbalanced chromosome translocation (<1%)
- Unidentified (10%)

Prenatal screening

- Maternal testing does not exclude somatic and/or germline mosaicism
 - Prenatal testing is recommended for subsequent pregnancies of couples who have a previous child with AS
- Methylation testing is not offered on chorionic villus samples
 - Incomplete methylation in early embryonic development may cause false-positive results

Test Interpretation

See table

Reference

Lossie AC, Whitney MM, et al. Distinct phenotypes distinguish the molecular classes of Angelman syndrome. *J Med Genet.* 2001;38:834-835

	DNA Methylation	UBE3A Gene Sequencing
Clinical sensitivity	78% (Lossie, 2001)	11% (Lossie, 2001)
Analytical sensitivity	99%	99%
Positive result	<ul style="list-style-type: none">• Absence of methylated maternal allele confirms AS• Follow-up with fluorescence in situ hybridization (FISH) or array comparative genomic hybridization (CGH) determines whether deletion is present<ul style="list-style-type: none">○ If large deletion is present<ul style="list-style-type: none">▪ Order chromosome analysis in mother to exclude rearrangement (alters recurrence risk)○ If FISH is normal<ul style="list-style-type: none">▪ Order DNA polymorphism analysis to distinguish between UPD and imprinting defect○ If no UPD<ul style="list-style-type: none">▪ Order further DNA studies to detect imprinting defect• Paternal testing may be necessary	Confirms diagnosis in symptomatic individual
Inconclusive result	N/A	Gene variant detected, but whether the variant is benign or pathogenic is unclear
Limitations	<ul style="list-style-type: none">• Specific molecular mechanism responsible for abnormal methylation results cannot be determined• AS resulting from molecular mechanisms that do not affect methylation patterns will not be identified• Diagnostic errors can occur due to rare sequence variations	<ul style="list-style-type: none">• Regulatory mutations, deep intronic mutations, and large deletions/duplications will not be detected• Diagnostic errors may occur due to rare sequence variations